Genotype/phenotype comparisons: A probe for the effect of disease progression on drug metabolism

Current Opinion in Drug Discovery and Development

Volumn 5, Issue 1, 2002, Pages 144-149

  Williams, Marion L ^a   Wainer, Irving W ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Advanced disease; Cancer; CYP2C19; Genotype; HIV+ AIDS; N acetyltransferase 2; Phenotype

Indexed keywords

ACYLTRANSFERASE; CYCLOPHOSPHAMIDE; CYTOCHROME P450 2C19; CYTOCHROME P450 3A; DOCETAXEL; DRUG METABOLIZING ENZYME; HEXOBARBITAL; PHENAZONE; THEOPHYLLINE;

ACETYLATOR PHENOTYPE; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADVANCED CANCER; DISEASE COURSE; DRUG CLEARANCE; DRUG HYDROXYLATION; DRUG METABOLISM; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; REVIEW;

ANIMALS; DISEASE PROGRESSION; GENOTYPE; HIV INFECTIONS; HUMANS; NEOPLASMS; PHARMACEUTICAL PREPARATIONS; PHENOTYPE;

EID: 0036241208     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Anorexia during acute and chronic disease
2. Regulation of cytochromes P-450 during inflammation and infection
3. Hepatic cytochrome P450 regulation in disease states
4. Endotoxin administration to humans inhibits hepatic cytochrome P450-mediated drug metabolism
5. Endotoxin depresses hepatic cytochrome P450-mediated drug metabolism in women
6. Role of viral infections in the induction of adverse drug reactions
7. Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV-infected subjects: ACTG 884
8. Influence of nutrients and other dietary materials on cytochrome P-450 enzymes
9. Human cytochrome P450: Problems and prospects
10. Molecular mechanisms of genetic polymorphisms of drug metabolism
11. Molecular genetics of the debrisoquin-sparteine polymorphism
12. The demethylenation of methylenedioxymethamphetamine ('ecstasy') by debrisoquine hydroxylase (CYP2D6)
13. Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans
14. Acetylation phenotype and cutaneous hypersensitivity to trimethoprim-sulphamethoxazole in HIV-infected patients
15. N-acetylation among HIV positive patients and patients with AIDS: When is fast, fast and slow, slow?
16. Prospective evaluation of detoxification pathways as markers of cutaneous adverse reactions to sulphonamides in AIDS
17. Wasting syndrome: Nutritional support in HIV infection
18. Cancer and acquired immunodeficiency syndrome wasting syndromes: Current and future therapies
19. Nutritional support of the surgical oncology patient
20. A phase II study: Docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma
21. Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: Enzyme specificity, interindividual distribution and metabolic contribution in human liver
22. Effects of liver disease on pharmacokinetics
23. A discordance of the CYP2C19 genotype and phenotype in patients with advanced cancer
24. The influence of dietary protein deficiency on the microsomal metabolism of testosterone in the rat
25. Cytokine activity in cancer-related anorexia/cachexia: Role of megestrol acetate and medroxyprogesterone acetate
26. Biomedicine. Protein loss in cancer cachexia
27. Wasting in cancer
28. Characterization of a cancer cachectic factor
29. Identification of proteolysis inducing factors (PIF) in the urine of cancer patients with cachexia
30. Characteristics of patients with pancreatic cancer expressing a novel cancer cachectic factor
31. Investigation of the potential of capillary electrophoresis with off-line matrix-assisted laser desorption/ionization time of flight mass spectrometry for clinical analysis: Examination of a glycoprotein factor associated with cancer cachexia
32. Proteolysis inducing factor is expressed in tumours of patients with gastrointestinal cancers and correlates with weight loss
33. Genotype and phenotype of cytochrome P450 2D6 in human immunodeficiency virus-positive patients and patients with acquired immunodeficiency syndrome
34. Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians